Suzuki I, Senda H, Yokota T
J Antibiot (Tokyo). 1985 Feb;38(2):249-58. doi: 10.7164/antibiotics.38.249.
The protective activity of cefbuperazone (T-1982) was compared with those of latamoxef, cefotaxime, and cefmetazole against intraperitoneal and urinary tract infections in mice. In both tests, cefbuperazone manifested a higher activity than the other cephems against infections with Escherichia coli and Klebsiella pneumoniae. Cefbuperazone also showed a comparatively high degree of prophylactic effect; this activity was observed even when given 4 hours before bacterial challenge. The good in vivo activity of cefbuperazone could not be explained by the differences between the antibiotics on the basis of the serum levels and vitro activity. Mice, treated with cefbuperazone, showed a statistically significant prolongation of survival time against intraperitoneal challenge with Candida albicans, but not when treated with the other cephems. This finding suggests that the host defense mechanisms stimulated by cefbuperazone may contribute to the good in vivo activity of this antibiotic.
将头孢哌酮(T-1982)与拉氧头孢、头孢噻肟和头孢美唑对小鼠腹腔感染和尿路感染的保护活性进行了比较。在两项试验中,头孢哌酮对大肠杆菌和肺炎克雷伯菌感染表现出比其他头孢菌素更高的活性。头孢哌酮还显示出较高程度的预防作用;即使在细菌攻击前4小时给药也观察到这种活性。头孢哌酮良好的体内活性不能用基于血清水平和体外活性的抗生素差异来解释。用头孢哌酮治疗的小鼠,在腹腔注射白色念珠菌攻击时,存活时间有统计学意义的延长,但用其他头孢菌素治疗时则没有。这一发现表明,头孢哌酮刺激的宿主防御机制可能有助于这种抗生素良好的体内活性。